GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
- Conditions
- Asthma
- Interventions
- Drug: Higher-dose inhaled corticosteroidsDrug: Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7779
- Registration Number
- NCT01431924
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 238
- Registration Number
- NCT01431950
- Locations
- 🇷🇺
GSK Investigational Site, Pyatigorsk, Russian Federation
Amoxicillin Bioequivalence Study Brazil - Fast
- Conditions
- Infections, Bacterial
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01431989
- Locations
- 🇧🇷
GSK Investigational Site, Goiania, Goiás, Brazil
Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01431976
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2016-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT01431963
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT01431937
- Locations
- 🇦🇺
GSK Investigational Site, Nedlands, Western Australia, Australia
Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT01428544
Japanese Phase 1 Study of GSK2585823
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01428466
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT01428531
Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors
- Conditions
- Leukaemia, Myelocytic, Acute
- Interventions
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT01428427
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States